Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Lapaquistat acetate and atorvastatin
Drug: Atorvastatin

First Posted Date: 2005-09-02

Last Posted Date: 2012-05-24

Lead Sponsor: Takeda

Target Recruit Count: 448

Registration Number: NCT00143676

Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol

Phase 3

Completed

Conditions: Dyslipidemia

Interventions: Drug: Placebo
Drug: Lapaquistat Acetate

First Posted Date: 2005-09-02

Last Posted Date: 2012-05-24

Lead Sponsor: Takeda

Target Recruit Count: 361

Registration Number: NCT00143663

Efficacy & Safety of Resatorvid in Adults With Severe Sepsis

Phase 3

Completed

Conditions: Sepsis

Interventions: Drug: Resatorvid
Drug: Placebo

First Posted Date: 2005-09-02

Last Posted Date: 2012-02-02

Lead Sponsor: Takeda

Target Recruit Count: 277

Registration Number: NCT00143611

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

Phase 2

Terminated

Conditions: Papillomavirus Infections

Interventions: Drug: 851B

First Posted Date: 2005-07-11

Last Posted Date: 2016-08-19

Lead Sponsor: Takeda

Target Recruit Count: 240

Registration Number: NCT00117884

Febuxostat Versus Allopurinol Control Trial in Subjects With Gout

Phase 3

Completed

Conditions: Gout

Interventions: Drug: Febuxostat
Drug: Allopurinol

First Posted Date: 2005-01-31

Last Posted Date: 2012-02-02

Lead Sponsor: Takeda

Target Recruit Count: 760

Registration Number: NCT00102440

Venticute in Patients With Pneumonia or Aspiration of Gastric Contents and Intubation/Ventilation/Oxygenation Impairment (BY2001/M1-007)

Phase 3

Completed

Conditions: Pneumonia

First Posted Date: 2003-12-25

Last Posted Date: 2012-05-07

Lead Sponsor: Takeda

Target Recruit Count: 1200

Registration Number: NCT00074906

Locations: 🇬🇧
Altana Pharma/Nycomed, West Lothian, United Kingdom

Safety and Efficacy Study of Once and Twice Daily Doses of MCC-135 in Subjects With Congestive Heart Failure.

Phase 2

Completed

Conditions: Congestive Heart Failure

Interventions: Drug: Placebo
Drug: MCC-135

First Posted Date: 2002-11-21

Last Posted Date: 2012-02-02

Lead Sponsor: Takeda

Target Recruit Count: 204

Registration Number: NCT00050076

Locations: 🇺🇸
LAC & USC Medical Center, Los Angeles, California, United States
🇺🇸
Apex Research Institute, Santa Ana, California, United States
🇺🇸
Medical Group of Fort Wayne, PC, Fort Wayne, Indiana, United States

and more 48 locations

Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2

Phase 1

Completed

Conditions: Breast Neoplasm
Pancreatic Neoplasm
Lung Neoplasm
Ovarian Neoplasm
Renal Neoplasm

Interventions: Drug: TAK-165

First Posted Date: 2002-04-25

Last Posted Date: 2012-02-02

Lead Sponsor: Takeda

Target Recruit Count: 16

Registration Number: NCT00034281

Locations: 🇺🇸
The Institute for Drug Development, San Antonio, Texas, United States
🇺🇸
South Texas VA, Audie Murphy Division, San Antonio, Texas, United States
🇺🇸
Arizona Cancer Center, Scottsdale, Arizona, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy